
Current psoriasis therapies have little‐to‐no effect on comorbidities such as obesity and chronic obstructive pulmonary disease (COPD). Apremilast, a phosphodiesterase 4 (PDE‐4) inhibitor, is approved for moderate‐to‐severe psoriasis and considered a safe treatment option, that does not require laboratory monitoring. Nonetheless, lower efficacy compared with novel similar priced biologics, have led to modest use of apremilast in some countries...
Like
Save
Share